Zhi, Jianguo
11Roche Innovation Center New York, New York.
3 papers on CoChatORCID 0000-0001-5837-4687
Most cited papers
- Verified
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology
Sarcoma Diagnosis and TreatmentCancer-related Molecular Pathways
Cited by 571
- Verified
Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research
Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research
Cited by 352
- Verified
Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2012) · Blood
Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free